cancer treatment

Timing of radiotherapy administration may significantly influence treatment efficacy in breast and prostate cancer. A Spanish study, published in Nature Communications, demonstrates that circadian oscillation of Cryptochrome 1 (CRY1) modulates DNA double-strand break (DSB) repair, making radiotherapy more effective in…

In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…

The launch of World Psycho-Oncology Day signals growing momentum behind psychosocial care in cancer, but without structural change, millions of patients will continue to go without the support they need. With the announcement of World Psycho-Oncology Day (WPOD), to be…

Sixteen years ago, Dr. Michael Gnant was portrayed in CancerWorld as a surgical oncologist unafraid to push boundaries in breast cancer care. Today, his perspective reflects not retreat but evolution. The boundary-pusher remains, but his focus has widened. His work…

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…

“I’m a scientist first and foremost. I don’t remember a time not thinking about being a scientist.” What Karen Knudsen, the CEO of Parker Institute for Cancer Immunotherapy, remembers clearly is the pull not toward prestige or power, but toward…

Chimeric antigen receptor natural killer T (CAR-NKT) cell therapy, a novel form of immunotherapy, is emerging as a promising ‘off-the-shelf’ treatment for patients with pancreatic cancer. In a study published in PNAS, November 21, 2025, U.S. investigators report that CAR-NKT cells…

Could artificial sweeteners undo the benefits of immunotherapy? A study published in Cancer Discovery, July 30, found that melanoma and non-small cell lung cancer (NSCLC) patients who consume high levels of the artificial sweetener sucralose have worse responses to immunotherapy…

From Rome to Milan to ESMO’s presidency — a story of science, courage, and mentorship. I am in Yerevan. Giuseppe Curigliano is in Milan, just back from Asia. “JSMO, CSCO, Korea, Japan, China…” he sighs, then laughs. “Too much travel?”…

Selective serotonin reuptake inhibitors (SSRIs) enhanced the ability of T cells to fight cancer and suppressed tumour growth across a range of cancer types in both mouse and human tumour models. The study, published in Cell, May 20, further showed…